Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I study to assess the safety, tolerability, and pharmacokinetics of enteric-coated buprenorphine (BuTab) in healthy subjects

Trial Profile

A phase I study to assess the safety, tolerability, and pharmacokinetics of enteric-coated buprenorphine (BuTab) in healthy subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jan 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Buprenorphine (Primary)
  • Indications Opioid-related disorders; Pain
  • Focus Adverse reactions; Pharmacokinetics; Proof of concept
  • Sponsors Relmada Therapeutics
  • Most Recent Events

    • 11 Jan 2016 Top-line results will be presented at 2016 Biotech Showcase™ in San Francisco Presentation on January 13, 2016, as per Relmada Therapeutics media release.
    • 08 Dec 2015 According to Relmada Therapeutics media release, positive topline results of oral formulation of buprenorphine were announced.
    • 07 Dec 2015 According to a Relmada Therapeutics media release, data from this study are expected before the end of 2015.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top